Baker Avenue Asset Management, LP Sage Therapeutics, Inc. Transaction History

Baker Avenue Asset Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $351 - $1,028	21 Added 175.0%	33 $0
Q4 2022 Feb 13, 2023	BUY	$32.2 - $43.61 $386 - $523	12 New	12 $0
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $126,378 - $325,017	-2,100 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $142,065 - $164,781	-900 Reduced 30.0%	2,100 $384,000
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $267,990 - $490,950	3,000 New	3,000 $477,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Baker Avenue Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Baker Avenue Asset Management, LP with notifications on news.